Candel Therapeutics Inc (CADL)

Jan 13, 2025, 8:00 AM EST - 4 days ago

Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025

Jan 2, 2025, 11:46 PM EST - 15 days ago

Best-Performing Stocks Of 2024

APP BYRN DAVE INOD JANX LUNR MSTR

Dec 16, 2024, 4:01 PM EST - 4 weeks ago

Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Dec 13, 2024, 8:53 AM EST - 5 weeks ago

Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session

EGHT

Dec 12, 2024, 11:00 PM EST - 5 weeks ago

Candel Therapeutics Announces Pricing of Public Offering

Dec 12, 2024, 4:51 PM EST - 5 weeks ago

Candel Therapeutics Announces $80 Million Proposed Public Offering

Dec 11, 2024, 12:19 PM EST - 5 weeks ago

Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight

Dec 11, 2024, 9:19 AM EST - 5 weeks ago

Candel Therapeutics Stock Surges Over 100% - Here's Why

Dec 11, 2024, 7:09 AM EST - 5 weeks ago

Candel Therapeutics' cancer drug meets late-stage trial goals

Dec 11, 2024, 7:00 AM EST - 5 weeks ago

Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

Nov 5, 2024, 9:00 AM EST - 2 months ago

Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma

Nov 1, 2024, 12:40 PM EDT - 2 months ago

Candel Therapeutics: A Low-Price Oncolytic Virus Plays Further Along Than You Think

Oct 4, 2024, 9:00 AM EDT - 3 months ago

Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting

Jul 29, 2024, 3:32 PM EDT - 6 months ago

3 Biotech Names With Potential Catalysts By Year End

RCKT VRDN

Jun 11, 2024, 8:00 AM EDT - 7 months ago

Candel Therapeutics to Join Russell 3000® Index

May 30, 2024, 8:00 AM EDT - 8 months ago

FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma

May 23, 2024, 5:00 PM EDT - 8 months ago

Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting

May 22, 2024, 8:00 AM EDT - 8 months ago

Candel Therapeutics to Present at the Jefferies Global Healthcare Conference

May 20, 2024, 8:00 AM EDT - 8 months ago

Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting

May 14, 2024, 8:00 AM EDT - 8 months ago

Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Apr 25, 2024, 8:00 AM EDT - 9 months ago

Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting

Apr 15, 2024, 4:35 PM EDT - 9 months ago

Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer

Apr 11, 2024, 9:00 AM EDT - 10 months ago

Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer

Apr 9, 2024, 8:00 AM EDT - 10 months ago

Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors

Apr 5, 2024, 8:56 AM EDT - 10 months ago

Candel Therapeutics stock jumps as pancreatic cancer treatment shows promise

Apr 5, 2024, 8:28 AM EDT - 10 months ago

Candel Therapeutics stock soars 30%: find out more

Apr 4, 2024, 8:00 AM EDT - 10 months ago

Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Mar 28, 2024, 4:05 PM EDT - 10 months ago

Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma

Mar 28, 2024, 8:05 AM EDT - 10 months ago

Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights

Mar 6, 2024, 8:00 AM EST - 11 months ago

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

BLRX IMRX ONCY

Mar 5, 2024, 4:30 PM EST - 11 months ago

Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate

Feb 13, 2024, 7:30 AM EST - 1 year ago

CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma

Feb 5, 2024, 8:00 AM EST - 1 year ago

Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts

Dec 12, 2023, 8:00 AM EST - 1 year ago

Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer

Nov 28, 2023, 9:00 AM EST - 1 year ago

Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409

Nov 9, 2023, 8:00 AM EST - 1 year ago

Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Nov 4, 2023, 8:00 AM EDT - 1 year ago

Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC

Nov 3, 2023, 12:00 PM EDT - 1 year ago

Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Oct 18, 2023, 11:00 AM EDT - 1 year ago

Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110

Sep 27, 2023, 9:40 AM EDT - 1 year ago

Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting

Sep 26, 2023, 8:00 AM EDT - 1 year ago

Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer

Sep 6, 2023, 8:00 AM EDT - 1 year ago

Candel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Aug 10, 2023, 8:00 AM EDT - 1 year ago

Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Aug 2, 2023, 8:00 AM EDT - 1 year ago

Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference

Jun 13, 2023, 8:00 AM EDT - 1 year ago

Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024

Jun 8, 2023, 8:00 AM EDT - 1 year ago

Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors

Jun 5, 2023, 8:00 AM EDT - 1 year ago

Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference

May 19, 2023, 9:00 AM EDT - 1 year ago

Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

May 11, 2023, 8:00 AM EDT - 1 year ago

Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

May 2, 2023, 8:00 AM EDT - 1 year ago

Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO